Autoantibodies to agrin in myasthenia gravis patients

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhang, Bin ^a,b   Shen, Chengyong ^a,f   Bealmear, Beverly ^c   Ragheb, Samia ^c,d   Xiong, Wen Cheng ^a,f   Lewis, Richard A ^c,e   Lisak, Robert P ^c   Mei, Lin ^a,f  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; AUTOANTIBODY; AUTOANTIGEN; CHOLINERGIC RECEPTOR; LIPOPROTEIN; PROTEOGLYCAN; MUSK PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN TYROSINE KINASE;

ANTIBODY DETECTION; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MOTONEURON; MUSCLE CELL; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; BLOOD; IMMUNOLOGY; METABOLISM; PHOSPHORYLATION;

AGRIN; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; MYASTHENIA GRAVIS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 84897981976     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091816     Document Type: Article

References (69)

1. Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. Lancet 357: 2122-2128. (Pubitemid 32607461)
2. Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10: 46.
3. Phillips LH Jr (2003) The epidemiology of myasthenia gravis. Ann N Y Acad Sci 998: 407-412.
4. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72: 1548-1554.
5. Richman DP, Agius MA (2003) Treatment of autoimmune myasthenia gravis. Neurology 61: 1652-1661. (Pubitemid 38020807)
6. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
7. Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48: 1246-1252. (Pubitemid 16229407)
8. Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptor. Science 180: 871-872.
9. Christadoss P, Krco CJ, Lennon VA, David CS (1981) Genetic control of experimental autoimmune myasthenia gravis in mice. II. Lymphocyte proliferative response to acetylcholine receptor is dependent on Lyt-1+23- cells. J Immunol 126: 1646-1647. (Pubitemid 11149281)
10. Lindstrom JM, Lennon VA, Seybold ME, Whittingham S (1976) Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci 274: 254-274.
11. Kao I, Drachman DB (1977) Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 196: 527-529. (Pubitemid 8090465)
12. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365-368. (Pubitemid 32224355)
13. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978-1980. (Pubitemid 36736017)
14. Kumar V, Kaminski HJ (2011) Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 11: 89-96.
15. Kim JY, Park KD, Richman DP (2011) Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol 7: 173-183.
16. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, et al. (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69: 445-451.
17. Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, et al. (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259: 427-435.
18. Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69: 418-422.
19. Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, et al. (2013) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. Journal of autoimmunity.
20. Hall ZW, Sanes JR (1993) Synaptic structure and development: the neuromuscular junction. Cells 72 (Suppl): 99-121. (Pubitemid 23051239)
21. Sanes JR, Lichtman JW (1999) Development of the vetebrate neuromuscular junction. Annual Review of Neuroscience 22: 389-442.
22. Sanes JR, Lichtman JW (2001) Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci 2: 791-805. (Pubitemid 33674061)
23. Fallon JR, Hall ZW (1994) Building synapses: agrin and dystroglycan stick together. [Review]. Trends in Neurosciences 17: 469-473. (Pubitemid 24321947)
24. Rotundo RL (2003) Expression and localization of acetylcholinesterase at the neuromuscular junction. J Neurocytol 32: 743-766.
25. Wu H, Xiong WC, Mei L (2010) To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137: 1017-1033.
26. Froehner SC (1993) Regulation of ion channel distribution at synapses. Annual Review of Neuroscience 16: 347-368.
27. McMahan UJ, Horton SE, Werle MJ, Honig LS, Kroger S, et al. (1992) Agrin isoforms and their role in synaptogenesis. [Review]. Curr Opin Cell Biol 4: 869-874.
28. McMahan UJ (1990) The agrin hypothesis. [Review]. Cold Spring Harb Symp Quant Biol 55: 407-418.
29. Godfrey EW, Nitkin RM, Wallace BG, Rubin LL, McMahan UJ (1984) Components of Torpedo electric organ and muscle that cause aggregation of acetylcholine receptors on cultured muscle cells. Journal of Cell Biology 99: 615-627. (Pubitemid 14065187)
30. Wallace BG (1988) Regulation of agrin-induced acetylcholine receptor aggregation by Ca++ and phorbol ester. J Cell Biol 107: 267-278.
31. Campanelli JT, Hoch W, Rupp F, Kreiner T, Scheller RH (1991) Agrin mediates cell contact-induced acetylcholine receptor clustering. Cells 67: 909-916. (Pubitemid 121001505)
32. Fallon JR, Gelfman CE (1989) Agrin-related molecules are concentrated at acetylcholine receptor clusters in normal and aneural developing muscle. J Cell Biol 108: 1527-1535. (Pubitemid 19097057)
33. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, et al. (2008) LRP4 serves as a coreceptor of agrin. Neuron 60: 285-297.
34. Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, et al. (2008) Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135: 334-342.
35. DeChiara TM, Bowen DC, Valenzuela DM, Simmons MV, Poueymirou WT, et al. (1996) The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85: 501-512. (Pubitemid 26157189)
36. Lin W, Burgess RW, Dominguez B, Pfaff SL, Sanes JR, et al. (2001) Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse. Nature 410: 1057-1064. (Pubitemid 32391032)
37. Yang X, Arber S, William C, Li L, Tanabe Y, et al. (2001) Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation. Neuron 30: 399-410. (Pubitemid 32530584)
38. Gautam M, Noakes PG, Moscoso L, Rupp F, Scheller RH, et al. (1996) Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 85: 525-535. (Pubitemid 26157191)
39. Ruegg MA, Bixby JL (1998) Agrin orchestrates synaptic differentiation at the vertebrate neuromuscular junction. Trends Neurosci 21: 22-27. (Pubitemid 128766374)
40. Weatherbee SD, Anderson KV, Niswander LA (2006) LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 133: 4993-5000. (Pubitemid 46085064)
41. Wu H, Lu Y, Shen C, Patel N, Gan L, et al. (2012) Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron 75: 94-107.
42. Luo Z, Wang Q, Zhou J, Wang J, Liu M, et al. (2002) Regulation of AChR Clustering by Dishevelled Interacting with MuSK and PAK1. Neuron 35: 489-505. (Pubitemid 34879948)
43. Luo S, Zhang B, Dong XP, Tao Y, Ting A, et al. (2008) HSP90 beta regulates rapsyn turnover and subsequent AChR cluster formation and maintenance. Neuron 60: 97-110.
44. Zhang B, Luo S, Dong XP, Zhang X, Liu C, et al. (2007) Beta-catenin regulates acetylcholine receptor clustering in muscle cells through interaction with rapsyn. J Neurosci 27: 3968-3973. (Pubitemid 46597140)
45. Glass DJ, Bowen DC, Stitt TN, Radziejewski C, Bruno J, et al. (1996) Agrin acts via a MuSK receptor complex. Cell 85: 513-523. (Pubitemid 26157190)
46. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490.
47. Cossins J, Belaya K, Zoltowska K, Koneczny I, Maxwell S, et al. (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275: 123-128.
48. Gomez CM, Richman DP (1983) Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A 80: 4089-4093. (Pubitemid 13072778)
49. Lindstrom JM (2000) Acetylcholine receptors and myasthenia. Muscle Nerve 23: 453-477.
50. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ (1978) Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 298: 1116-1122. (Pubitemid 8340619)
51. Aharonov A, Tarrab-Hazdai R, Abramsky O, Fuchs S (1975) Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A 72: 1456-1459.
52. Engel AG, Tsujihata M, Lambert EH, Lindstrom JM, Lennon VA (1976) Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations. J Neuropathol Exp Neurol 35: 569-587.
53. Engel AG, Lambert EH, Howard FM (1977) Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52: 267-280. (Pubitemid 8113467)
54. Engel AG, Arahata K (1987) The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505: 326-332.
55. ter Beek WP, Martinez-Martinez P, Losen M, de Baets MH, Wintzen AR, et al. (2009) The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am J Pathol 175: 1536-1544.
56. Punga AR, Lin S, Oliveri F, Meinen S, Ruegg MA (2011) Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol 230: 207-217.
57. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, et al. (2006) Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 175: 107-117. (Pubitemid 43765734)
58. Shigemoto K, Kubo S, Jie C, Hato N, Abe Y, et al. (2008) Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 1132: 93-98. (Pubitemid 351841345)
59. Cole RN, Reddel SW, Gervasio OL, Phillips WD (2008) Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 63: 782-789. (Pubitemid 351945537)
60. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, et al. (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55: 580-584. (Pubitemid 38391977)
61. Tsiamalos P, Kordas G, Kokla A, Poulas K, Tzartos SJ (2009) Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol 16: 925-930.
62. Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, et al. (2004) Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30: 55-60. (Pubitemid 38880325)
63. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, et al. (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 76: 1099-1102. (Pubitemid 41081284)
64. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, et al. (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57: 444-448. (Pubitemid 40343969)
65. Saka E, Topcuoglu MA, Akkaya B, Galati A, Onal MZ, et al. (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65: 782-783; author reply 782-783.
66. Suhail H, Subbiah V, Singh S, Behari M (2010) Serological and clinical features of patients with myasthenia gravis in north Indian population. Int J Neurosci 120: 115-119.
67. Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, et al. (2013) Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123: 5190-5202.
68. Gesemann M, Denzer AJ, Ruegg MA (1995) Acetylcholine receptor-aggregating activity of agrin isoforms and mapping of the active site. Journal of Cell Biology 128: 625-636.
69. Ferns MJ, Campanelli JT, Hoch W, Scheller RH, Hall Z (1993) The ability of agrin to cluster AChRs depends on alternative splicing and on cell surface proteoglycans. Neuron (USA) 11: 491-502. (Pubitemid 23287076)